In the meantime, TD Cowen downgraded its Cytek BioSciences Inc [CTKB] rating to a Hold from a a Buy in a research note published recently. A number of analysts have revised their coverage, including Goldman’s analysts, who decreased its forecast for the stock in late January from “a Buy” to “a Sell”. Stephens began covering CTKB with “an Overweight” recommendation on December 14, 2023. Raymond James started covering the stock on July 19, 2023. It rated CTKB as “a Mkt perform”.
Price Performance Review of CTKB
On Tuesday, Cytek BioSciences Inc [NASDAQ:CTKB] saw its stock fall -1.32% to $2.98. Over the last five days, the stock has lost -19.02%. Cytek BioSciences Inc shares have fallen nearly -54.08% since the year began. Nevertheless, the stocks have fallen -51.94% over the past one year. While a 52-week high of $7.63 was reached on 01/14/25, a 52-week low of $2.87 was recorded on 05/13/25. SMA at 50 days reached $3.89, while 200 days put it at $5.28.
Levels Of Support And Resistance For CTKB Stock
The 24-hour chart illustrates a support level at 2.83, which if violated will result in even more drops to 2.68. On the upside, there is a resistance level at 3.11. A further resistance level may holdings at 3.24. The Relative Strength Index (RSI) on the 14-day chart is 29.77, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.62, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 84.65%. Stochastics %K at 11.19% indicates the stock is a buying.
